Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera, Inc. director and co-founder Sheena Jonathan reported the vesting of 7,450 shares of Common Stock on January 14, 2026. These shares vested under a performance-based Restricted Stock Unit award granted on January 27, 2023, after a milestone tied to time and business performance criteria was certified. Following this vesting, she holds 270,031 shares of Common Stock directly. She also has indirect beneficial ownership of 22,532 shares held by Caraluna 1 Trust and 22,532 shares held by Caraluna 2 Trust.
Natera, Inc. furnished a current report stating that on January 11, 2026, it issued a press release with preliminary financial results for its fourth quarter and full fiscal year ended December 31, 2025. The press release is included as Exhibit 99.1, giving investors an early look at the company’s recent performance ahead of full audited results. The company specifies that this information, including Exhibit 99.1, is being furnished rather than filed, which means it is not subject to certain liability provisions under the securities laws or automatically incorporated into other SEC filings unless expressly referenced.
A Natera, Inc. director and co‑founder reported recent changes in their holdings of the company’s common stock. On December 15, 2025, they donated 1,060 shares as a charitable contribution at a reported price of $0.
On December 17, 2025, they sold 1,592, 1,348 and 130 shares in separate transactions at weighted average prices of $226.5404, $227.4355 and $228.2831 per share, effected under a Rule 10b5‑1 trading plan adopted on December 11, 2024. After these transactions, the reporting person directly beneficially owned 222,966 shares, with an additional 23,282 shares held in each of two Caraluna trusts for beneficiaries, over which they disclaim beneficial ownership.
An officer of Natera, Inc. who serves as President, Clinical Diagnostics reported multiple equity transactions in December 2025. On 12/12/2025, the officer made a charitable gift of 180 common shares, exercised 8,876 and 13,500 stock options at an exercise price of $9.59 per share, and sold 4,692 shares at an average price of $230.7575 to cover the option exercise price and tax obligations. On 12/15/2025, the officer made an additional charitable gift of 115 shares. After these transactions, the officer directly owns 126,450 common shares and holds 5,125 stock options at $9.59 per share, which are fully exercisable and expire on 04/07/2026.
Natera, Inc. reported insider activity by a company director involving both equity awards and stock sales. On 10/31/2025, the director received 132 Restricted Stock Units (RSUs) in lieu of a $23,750 quarterly cash retainer for board service, and these RSUs were fully vested at issuance, with each RSU representing one share of common stock.
Following this grant, the director held 68,761 common shares directly. On 12/12/2025, the director sold several blocks of Natera common stock: 14,372 shares at a weighted average price of $226.6174, 21,910 shares at $227.3532, 11,987 shares at $228.4858, and 150 shares at $229.095, all in multiple trades within narrow price ranges. After these transactions, the director directly owned 20,342 Natera shares.
Natera, Inc. reported an insider transaction by an officer serving as its SEC. and Chief Legal Officer. On December 4, 2025, this officer exercised stock options to acquire 6,902 shares of Natera common stock at an exercise price of $19.68 per share, converting derivative securities into common stock.
Following the transaction, the officer directly beneficially owned 208,601 shares of Natera common stock. The filing also shows 5,598 remaining stock options with a $19.68 exercise price, expiring on March 21, 2029, and notes that the option shares are fully exercisable.
Natera, Inc. (NTRA) reported insider selling by a director on a Form 4. On November 24, 2025, estate planning vehicles associated with the reporting person sold multiple blocks of Natera common stock, each reported as open-market sales. The trades used weighted average prices, with individual transactions occurring in ranges from $228.70 to $239.07 per share.
After the reported sales, the director indirectly beneficially owned 1,154,198 shares of Natera common stock through estate planning vehicles. One footnote states this indirect position includes 4,411 shares transferred to an estate planning vehicle in a transaction exempt from Section 16. The pricing details are available in ranges, and the reporting person has undertaken to provide exact breakdowns of shares sold at each price upon request.
Natera, Inc. (NTRA) director and co‑founder reported open‑market sales of company stock. On 11/20/2025, the reporting person sold 10,000 shares of Natera common stock at a weighted average price of $225.0816 per share under a Rule 10b5‑1 trading plan adopted on December 11, 2024, and continued to hold 222,660 shares directly afterward.
On 11/21/2025, 2,000 shares were sold at a weighted average price of $230.0097 per share through the Caraluna 1 Trust and 2,000 shares were sold at a weighted average price of $230.0055 per share through the Caraluna 2 Trust, both under a separate Rule 10b5‑1 trading plan adopted on June 7, 2024, leaving 23,282 shares held in each trust. The shares in the trusts are held for the benefit of the trust beneficiaries, and the reporting person disclaims beneficial ownership of those securities.
Natera, Inc. director reports option exercises and share sales. A Natera director filed a Form 4 showing multiple transactions in Natera common stock on November 19 and 20, 2025. The director exercised stock options to acquire 5,112 shares at an exercise price of $40.93 on November 19, and then exercised options for 600 shares at $40.93 and 7,068 shares at $41.19 on November 20. On the same dates, the director sold several blocks of Natera common stock in open market transactions at weighted average prices ranging from about $213.18 to $224.92 per share, under a Rule 10b5-1 trading plan adopted on August 20, 2025. Following these transactions, the director reported owning 18,359 shares of Natera common stock directly and no remaining options in the reported option grants.
Natera (NTRA) director and co‑founder reported open‑market sales of common stock under Rule 10b5‑1 plans. On 11/07/2025, multiple sales were executed at weighted average prices between $190.00 and $198.38, leaving 232,660 shares held directly after the transactions. On 11/11/2025, additional sales by the Caraluna 1 Trust and Caraluna 2 Trust occurred at weighted averages between $206.68 and $209.29; following these, each trust showed 25,282 shares. The reporting person disclaims beneficial ownership of the trust‑held shares.